Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose

International Journal of Antimicrobial Agents

Volumn 23, Issue SUPPL. 1, 2004, Pages 6-16

  Boy, Dieter ^a   Well, Michaela ^a   Kinzig Schippers, Martina ^b   Sörgel, Fritz ^b   Ankel Fuchs, Dorothe ^c   Naber, Kurt G ^a  

^a Urologische Klinik   (Germany)

^b Institute for Biomedical Research   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Ciprofloxacin; Gatifloxacin; Plasma concentration; Single oral dose; Urinary bactericidal activity; Urinary excretion

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GATIFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DILUTION; DOSE RESPONSE; DRUG BLOOD LEVEL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FLUORESCENCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SAPROPHYTICUS; STATISTICAL SIGNIFICANCE; TIME; URINALYSIS; URINARY EXCRETION; VOLUNTEER;

EID: 1642341270     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.006     Document Type: Conference Paper

References (27)

1. Naber K.G., Bartnicki A., Bishoff W.et al. Gatifloxacin 200. mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonepliritis or complicated urinary tract infections Int. J. Antimicrob. Agent. 2351:2004;41-53.
2. Naber KG, Antibacterial activity of antibacterial agents in urine: an overview of applied methods. In: Bergan T, editor. Infectiology, Urinary Tract Infections. Basel: Karger; 1997. p. 74-83.
3. Naber K.G., Theuretzbacher U., Kinzig M., Savov O., Sörgel F. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42:1998;1659-1665.
4. Naber C.K., Hammer M., Kinzig-Schippers M., Sauber C., Sörgel F., Bygate E.A.et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob. Agents Chemother. 45:2001;3524-3530.
5. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1998;1-12.
6. Edberg SC. The measurement of antibiotics in human body fluids: techniques and significance. In: Lorian V, editor. Antibiotics in Laboratory Medicine. Baltimore, MD: The Williams & Wilkins Co.; 1986. p. 466-7.
7. National Committee of Clinical and Laboratory Standards (NCCLS). Methods of determining bactericidal activity of antimicrobial agents. Tentative Guideline, September 1992. NCCLS document M26-T, vol. 12. 1992. p. 1-36.
8. Appelbaum P.C., Hunter P.A. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents. 16:2000;5-15.
9. Bryskier A., Chantot J.F. Classification and structure-activity relationships of fluoroquinolones. Drugs. 49:1995;16-28.
10. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials [Erratum in: J Antimicrob Chemother 1994;34:851] J Antimicrob Chemother 1994;33:685-706.
11. Tarshis G.A., Miskin B.M., Jones T.M., Champlin J., Wingert K.J., Breen J.D.et al. Once daily oral gatifloxacin vs. oral levofloxacin in the treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob. Agents Chemother. 45:2001;2358-2362.
12. Cox C.E., Marbury T.C., Pittman W.G., Brown G.L., Auerbach S.M., Fox B.C.et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin. Ther. 24:2002;223-236.
13. Richard G.A., Mathew C.P., Kirstein J., Orchard D., Young J., Fox B. Single (400. mg) and multiple (200 mg QD) dose oral gatifloxacin (GAT) vs. multiple (100 mg BID) dose oral ciprofloxacin (CIP) in the treatment of acute, uncomplicated urinary tract infection (UTI) in women [Abstract # 152] Clin. Infect. Dis. 29:1999;988.
14. Perry C.M., Ormrod D., Hurst M., Onrust S.V. Gatifloxacin, a review of its use in the management of bacterial infections. Drugs. 62:2002;169-207.
15. Kunin C.M. Urinary tract infections in females. Clin. Infect. Dis. 18:1994;1-12.
16. Naber K.G. Which fluoroquinolones are suitable for the treatment of urinary tract infections. Int. J. Antimicrob. Agents. 17:2001;331-341.
17. Naber K.G., Bergman B., Bishop M.C., Bjerklund-Johansen T.E., Botto H., Lobel B.et al. EAU Guidelines for the management of urinary and male genital tract infections. Eur. Urol. 40:2001;576-588.
18. Nicolle LE. Use of Quinolones in urinary tract infection and prostatitis. In: Andriole VT, editor. The Quinolones. 2nd ed. San Diego, London, Boston, New York, Sydney, Tokyo, Toronto: Academic Press; 1998. p. 417-29.
19. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 19:2002;261-268.
20. MacGowan A., Bowker K. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents. 19:2002;291-298.
21. Craig W.A. Re-evaluating current antibiotic therapy. Resp. Med. 95:2001;S12-S19.
22. Gunderson B.W., Ross G.H., Ibrahim K.H., Rotschafer J.C. What do we really know about antibiotic pharmacodynamics. Pharmacotherapy. 21:2001;302S-318S.
23. Andes DR, Craig WA. In vivo pharmacodynamic activity of gemifloxacin (GEM) against multiple bacterial pathogens. 39th ICAAC, San Francisco, 26-29 September 1999. Abstract 27.
24. Andes DR, Craig WA. In vivo pharmacodynamic activity of sitafloxacin (SIT) against multiple bacterial pathogens. 39th ICAAC, San Francisco, 26-29 September 1999. Abstract 28.
25. Andes DR, Craig WA. In vivo pharmacodynamic activity of gatifloxacin (GAT) against multiple bacterial pathogens. 39th ICAAC, San Francisco, 26-29 September 1999. Abstract 191.
26. Stahlberg H.J., Goehler K., Guillaume M., Mignot A. Single dose pharmacokinetics of the R- and S-enantiomers of gatifloxacin in volunteers. Drugs. 58:1999;222-224.
27. Shah A., Liu M.C., Vaughan D., Heller A.H. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500. mg tablet compared with 500 mg/10 ml or 500 mg/5 ml suspension and the effect of food on the absorption of ciprofloxacin oral suspension J. Antimicrob. Chemother. 43:1999;49-54.